A phase I/II Trial to Compare the Immunogenicity and Safety of 3 DNA C Prime Followed by 1 NYVAC C Boost to 2 DNA C Prime Followed by 2 NYVAC C Boost.
Phase of Trial: Phase I/II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs HIV DNA vaccine; HIV vaccine
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 16 Feb 2010 Interim results presented at the 17th Conference on Retroviruses and Opportunistic Infections.
- 17 Dec 2009 Planned number of patients changed from 140 to 147 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History